| Literature DB >> 30707305 |
Marta Perez-Somarriba1, Maitane Andión1, Miguel A López-Pino2, Cinzia Lavarino3, Luis Madero1, Alvaro Lassaletta4.
Abstract
Medulloblastoma is the most common malignant brain tumor in children. Approximately 30% of children with medulloblastoma will progress or relapse despite being treated. New therapies have been proposed in recent years, including high-dose chemotherapy, immunotherapy, and targeted therapy. However, the best treatment for these patients remains unclear, and in this situation prognosis is poor. Oral etoposide has been used as a single agent or in combination for treating relapsed brain tumors since the 1990s. We report an 8-year-old patient with recurrent metastatic medulloblastoma who had an excellent response after treatment with oral etoposide, maintaining a great quality of life. As clinicians, we must always try to include our patients in clinical trials; however, when this is not possible, we should not forget that "old drugs" such as oral etoposide may work in some patients, with a good response of the tumor, and what is most important, providing the patient with a good quality of life.Entities:
Keywords: Chemotherapy; Children; Oral etoposide; Relapsed medulloblastoma
Mesh:
Substances:
Year: 2019 PMID: 30707305 DOI: 10.1007/s00381-019-04072-9
Source DB: PubMed Journal: Childs Nerv Syst ISSN: 0256-7040 Impact factor: 1.475